Gwendolyn Wu is a reporter at BioPharma Dive. She focuses on biotech startups, venture capital, and the healthcare ecosystem, with a particular emphasis on pharmaceuticals and medical specialties. Gwendolyn's work has been featured in notable publications including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
By: Gwendolyn Wu
The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
